Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06375811 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

Study acronym: PREGnant
StatusActive, Not Recruiting
PhasePhase 3
Started2024-03-16
View on ClinicalTrials.gov ↗

Amendment history

2026-06-03
notable
Recruiting→Active, Not Recruiting Study Status, Oversight, Study Design, Contacts/Locations v4
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2026-06-30→2027-03-31
Completion date2026-09-30→2027-03-31
Enrollment targetestimated 297→confirmed 97
Study sitesdetails revised at 5 of 5 sites
2025-07-21
minor
Study Identification, Study Status, Study Design v3
Enrollment target288→297
2025-03-06
minor
Study Status, Oversight, Contacts/Locations v2
Completion date2026-06-30→2026-09-30
Study sitescontacts updated at 3 of 5 sites
2024-04-18
minor
Study Status, Arms and Interventions, IPDSharing v1
Re-verified, no change to tracked fields
2024-04-16
minor
Original filing
487 trials monitored
See 35 trials at risk
A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.
Trial Details
NCT Number NCT06375811
Lead Sponsor Yale University
Collaborators: University of Colorado, Denver, Northwestern University, University of North Carolina, Duke University, Johns Hopkins University
Conditions Infertility, Endometriosis
Enrollment 97 participants
Start Date 2024-03-16
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05